Xtant Medical (XTNT) director reports new 553,797-share DSU award

Q: What insider transaction did XTNT report in this Form 4?

The Form 4 reports that a director of Xtant Medical Holdings, Inc. (XTNT) received 553,797 shares of common stock on November 15, 2025 through a deferred stock unit (DSU) award granted under the company’s Amended and Restated 2023 Equity Incentive Plan.

Q: When do the newly granted XTNT deferred stock units vest?

The 553,797 DSUs will vest on November 15, 2026 , provided the reporting person continues to serve as a director of Xtant Medical Holdings, Inc. through that vesting date.

Q: How many XTNT shares are tied to deferred stock units for this director?

The beneficial ownership total includes 1,520,215 shares that are issuable upon settlement of deferred stock units granted under the Amended and Restated 2023 Equity Incentive Plan, which remain subject to service-based vesting conditions.

Q: Is there a cash price associated with the XTNT shares reported in this transaction?

The Form 4 shows the price for the 553,797 acquired shares as $0 , reflecting that they were granted as part of a deferred stock unit equity award rather than purchased for cash on the open market.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Xtant Medical Holdings, Inc. director equity grant reported

A director of Xtant Medical Holdings, Inc. (XTNT) reported receiving 553,797 shares of common stock on November 15, 2025 through a deferred stock unit (DSU) award under the company’s Amended and Restated 2023 Equity Incentive Plan. The DSUs will vest on November 15, 2026, provided the director remains on the board through that date, and each DSU represents a contingent right to receive one share of common stock, with settlement deferred to a later date under the award terms.

Following this award, the director beneficially owns 7,515,570 shares on a direct basis, which includes 1,520,215 shares issuable upon settlement of DSUs that are subject to continued service-based vesting conditions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Vizirgianakis Stavros G.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	553,797	$0.00	--

Holdings After Transaction: Common Stock — 7,515,570 shares (Direct)

Footnotes (1)

These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock. Includes 1,520,215 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

11/18/2025 - 05:34 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vizirgianakis Stavros G.

(Last)

(First)

(Middle)

C/O XTANT MEDICAL HOLDINGS, INC.

664 CRUISER LANE

(Street)

BELGRADE

59714

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Xtant Medical Holdings, Inc. [ XTNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/15/2025		A		553,797⁽¹⁾	A	$0	7,515,570⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

2. Includes 1,520,215 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

	/s/ Amy Culbert, attorney-in-fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did XTNT report in this Form 4?

The Form 4 reports that a director of Xtant Medical Holdings, Inc. (XTNT) received 553,797 shares of common stock on November 15, 2025 through a deferred stock unit (DSU) award granted under the company’s Amended and Restated 2023 Equity Incentive Plan.

When do the newly granted XTNT deferred stock units vest?

The 553,797 DSUs will vest on November 15, 2026, provided the reporting person continues to serve as a director of Xtant Medical Holdings, Inc. through that vesting date.

How many XTNT shares does the director beneficially own after this transaction?

After the reported transaction, the director beneficially owns 7,515,570 shares of XTNT common stock on a direct basis, including shares that may be issued upon settlement of deferred stock units.

How many XTNT shares are tied to deferred stock units for this director?

The beneficial ownership total includes 1,520,215 shares that are issuable upon settlement of deferred stock units granted under the Amended and Restated 2023 Equity Incentive Plan, which remain subject to service-based vesting conditions.

What does each Xtant Medical DSU represent in this Form 4?

Each deferred stock unit (DSU) reported in the filing represents a contingent right to receive one share of Xtant Medical Holdings, Inc. common stock, with settlement deferred in accordance with the DSU award agreement.

Is there a cash price associated with the XTNT shares reported in this transaction?

The Form 4 shows the price for the 553,797 acquired shares as $0, reflecting that they were granted as part of a deferred stock unit equity award rather than purchased for cash on the open market.